Introduction
Spinal and bulbar muscular atrophy (SBMA), or Kennedy disease (MIM 313200), is an X-linked recessive late-onset motor neurone disorder. Patients show slowly progressive spinal and bulbar muscular atrophy with fasciculations and generalised muscle weakness, frequently sensory symptoms and signs of partial androgen insensitivity, such as gynecomastia and impotence. 1, 2 SBMA is caused by a CAG repeat expansion in the first exon of the androgen receptor (AR) gene. 3 The gene normally has 10-36 CAG repeats, 4 but in SBMA patients the number of repeats is increased to 38-72. 5, 6 Several other neurodegenerative disorders caused by trinucleotide repeat expansions have also been reported. [7] [8] [9] It has been shown that proteins with expanded polyglutamine stretches encoded by the CAG repeats form fibrillary aggregates in neurones, leading to apoptosis. 10 Such aggregates have also been reported in SBMA. 4, 6, 11 The human AR gene is located in Xq11-q12. The gene contains 8 exons. 3 In the 3' end of the first exon of the AR gene, 1.2 kb downstream from the CAG repeat there is a polymorphic GGC repeat sequence. 12 In Japanese SBMA patients linkage disequilibrium between the CAG mutation and the intragenic GGC repeat has been found, indicating a founder effect. 13 The high prevalence of SBMA among Swedish-speaking people in the district of Vaasa in Western Finland 2 and in Northern Sweden (6 in 930 000) motivated us to search for linkage disequilibrium between the mutation and 17 microsatellite markers around the AR gene, and also to estimate the time when the SBMA mutation was introduced into Finland. Our initial studies showed that all 13 Finnish families shared identical alleles for at least five adjacent markers. This finding prompted us to extend the study to patients from the linguistically related neighbouring Scandinavian countries in the search for a genetic founder effect.
Material and methods
Thirteen Finnish families (FI-FXIII) with a total of 17 SBMA patients and four carriers, 10 Swedish families (SI-SX) with 13 patients, 12 Danish patients from different families (DI-DXII) and two Norwegian families (NI and NII) with three patients and three carriers were haplotyped for 17 microsatellite markers spanning a 25.2 cM region around the androgen receptor gene (Figure 1 ). A tentative age estimate in the Finnish sample based on the number of SBMA chromosomes, linkage disequilibrium observed, recombination fractions obtained from GDB and assumptions on ascertainment was made using the DMLE program (version 0.25). 14 We assumed complete isolation of the Finnish Swedish-speaking coastal population and a population growth equal to that generally estimated for Finland from mediaeval times (population base of about 100 000) from around year 1500 until the present (population base of about 5 million). As the algorithm carrying out the Monte Carlo replicates in DMLE only applies to marker loci with two allelic variants, only two loci were considered in the analysis, ALAS2 and DXS1125, the closest recombinant flanking loci to AR, both showing biallelic segregation in the Finnish SBMA families. For each log likelihood, a million Monte Carlo replicates were computed using a generation interval of 2. X-chromosomal inheritance was allowed for by simply halving the recombination fractions.
Results
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The 142 control chromosomes displayed a CAG repeat number ranging from 15 to 29 (Figure 2 ). The number of CAG repeats in the patients ranged from 38 to 51 (Figure 3 ). The range of CAG repeat numbers in Finnish patients was 41-47, with the mean of 44.3 ± 1.7. In Swedish patients the range of repeat numbers was 38-47, mean 43.6 ± 2.5. The Danish patients displayed 41-51 CAG repeats, mean 47 ± 3 ( Figure 3 ). The two Norwegian families had 43-45 repeats ( Table 1) . The difference between the CAG ranges of the Finnish and the Swedish patients was not statistically significant, but the Danish patients differed significantly from the others (P = 0.003).
The intragenic GGC repeat sizes ranged from 11 to 21 in controls, with 17 being the most common allele, present in 48% of the Finnish, 55% of the Swedish and 70% of the Danish controls (Figure 4) . All the Finnish, Swedish, Danish and Norwegian patients had 18 GGC repeats, also present in 26% of the Finnish, 27% of the Swedish and 15% of the Danish controls (P = 0.0001), suggesting linkage disequilibrium between the CAG repeat expansion and the GGC microsatellite.
Linkage disequilibrium was also seen between the mutation and the locus DXS1111, since allele 2 was present in 94.5% of the SBMA families and in only 40% of the Finnish, 18% of the Swedish and 25% of the Danish controls (P = 0.0001). All the Finnish, Swedish and Norwegian families shared the same allele 4 for the locus DXS135, which was present in 41% (P = 0.004) and 50% (P = 0.002) of the respective controls. However, allele 4 was seen in only one Danish family, the remaining 11 (92%) carrying allele 6 present in 20% of the Danish controls (P = 0.0003). All the Finnish, Swedish and Norwegian families shared allele 2 in DXS1213, present in 62% (P = 0.05) and 50% (P = 0.03) of the respective controls, and 11 (92%) of the Danish families had allele 3, present in 10% of the Danish controls (P = 0.08). Allele 3 of the locus DXS1194 was present in all except one (97%) patients, and also in 66% of the controls (P = 0.0002).
The maximum likelihood peak in the age estimation using the DMLE program (see Materials and methods for assumptions) for the closest recombinant flanking loci, ALAS2 and DXS1125, in the Finnish SBMA families was obtained at 20 generations for each (data not shown).
Discussion
All the Finnish and 9 of the 10 Swedish SBMA chromosomes harboured an identical haplotype spanning a 4.8 cM region (GDB) ( Table 1 ) on chromosome Xq11-q12. This suggests a common founder haplotype for these patients. The different alleles of the loci DXS1213 and DXS135 in the Danish SBMA patients compared to those carried by Finnish and Swedish patients indicate a more ancient separation. The DXS1194-DXS1111 haplotype shared by 92% of the families (Table 1) composes a potential Scandinavian founder haplotype. There was also evidence of migration between countries, since SI, Table 1 ) were quite similar, 44 and 45 repeats being the most common. The Danish patients had a somewhat wider range with slightly longer repeats, 49 repeats being the most common. If the Danish mutation had a more ancient origin, it would have had more time to develop a wider range. The comparable ranges shown here in the Finnish, Swedish and Norwegian patients suggest a more recent separation between these.
In Japanese SBMA patients linkage disequilibrium was found between the CAG repeat expansion and the GGC repeat, indicating a founder effect. 13 Nevertheless, in the Japanese patients the linkage disequilibrium was not as complete as in our study, where all Nordic patients shared the same GGC repeat number. A founder effect was also suggested to be responsible for the clustering of SCA6 families in the Nordrhein-Westfalia area in Germany, where the majority of the families shared allelic characteristics of three markers around the associated gene. 15 A founder effect has also been reported in SCA1, 16 SCA2 17, 18 and SCA3 (MachadoJoseph disease). 19 Twelve of the 13 Finnish SBMA families originated from the Vaasa region on the western coast of Finland. One patient (FVIII1) lived in Southern Finland. The fairly restricted area from which the SBMA patients originated and the fact that 11 of these 13 families were Swedish-speaking supports the theory of a common ancestor. Nevertheless, genealogical The Vaasa region in western Finland was inhabited during the Stone, Bronze and Iron Ages. Some later resettlement from Sweden is documented from mediaeval times, along with the expansion of Christianity, and later until the 18th century. Since many of the Swedish patients come from the areas located across the Gulf of Bothnia from the Vaasa region, and because of the common language, a common genetic background for the Finnish and the Swedish SBMA patients is indicated.
The maximum likelihood peak for ALAS2 and DXS1125 of the Finnish SBMA patients obtained by DMLE, 20 generations, would indicate the introduction of the SBMA mutation into the Finnish Swedish-speaking coastal population around 1400-1500. However, whilst the estimate seems close to the truth, it has very wide confidence limits and, on the other hand, is based for simplicity on assumptions that almost certainly are not the whole truth.
The fact that all the Scandinavian patients with SBMA carry the same intragenic GGC allele 18 in addition to other similarities in allele distribution suggests an ancient Scandinavian founder effect. There also seems to be a specific more extended sub-founder haplotype in each country. Later on, we plan to elucidate the possible similarities between patients from around the world, and to find out whether multiple founder effects exist.
